查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1815753

2025年雙胍類藥物全球市場報告

Biguanides Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年雙胍類藥物市場將穩定成長，到2029年將達到58.1億美元，複合年成長率為3.2%。預測期內成長的主要驅動力包括聯合治療的日益普及、藥物輸送技術的進步、研發投入的不斷增加、醫療保健支出的不斷成長以及在卵巢症候群(PCOS)治療中的應用不斷擴展。預測期內的主要趨勢包括對緩釋性開發的日益關注、對聯合療法的日益偏好、在腫瘤學中的應用不斷擴展，以及療效和安全性均有所提升的新型雙胍類藥物的出現。

我們預測未來五年該市場將成長3.2%，較我們先前對該市場的預測略有收縮0.5%。這一下降主要源自於美國與其他國家之間關稅的影響。貿易摩擦可能導致中國和以色列生產的二甲雙胍製劑價格上漲，從而擾亂美國的內分泌學實踐，導致2型糖尿病管理延遲，並增加3400萬美國患者的代謝紊亂治療費用。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，貿易摩擦的影響也將更加廣泛。

糖尿病盛行率的上升預計將在短期內推動雙胍類藥物市場的擴張。糖尿病是一種慢性代謝性疾病，其特徵是胰島素分泌不足導致血糖值升高。由於生活方式改變、人口老化、遺傳因素、診斷方法的改進和環境影響等多種因素，糖尿病的發生率正在上升。二甲雙胍等雙胍類藥物可透過提高胰島素敏感性、抑制肝醣生成和降低第 2 型糖尿病患者的血糖值來幫助控制糖尿病。例如，根據英國政府健康改善與差異辦公室的數據，從 2022 年 3 月到 2023 年 3 月，接受針對 1 型和 2 型糖尿病的所有八個建議護理步驟的人數比例都顯著增加。此外，達到 HbA1c 目標值的人數比例達到了創紀錄的 37.9%。因此，糖尿病盛行率的上升正在推動雙胍類藥物市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球雙胍類藥物：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球雙胍類市場：成長率分析
  • 全球雙胍類市場表現：規模與成長，2019-2024
  • 全球雙胍類市場預測：2024-2029年及2034年規模與成長
  • 全球雙胍類藥物：總潛在市場（TAM）

第6章 市場細分

  • 全球雙胍類藥物市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 二甲雙胍
  • 苯乙雙胍
  • 其他類型
  • 全球雙胍類藥物市場（按劑型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 藥片
  • 口服溶液
  • 全球雙胍類市場（按配方、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 即時發布
  • 延長釋放
  • 全球雙胍類市場：按分銷管道、實際情況和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 全球雙胍類藥物市場：依二甲雙胍類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 速釋二甲雙胍
  • 緩釋性二甲雙胍
  • 全球雙胍類藥物市場：依苯乙雙胍類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 鹽酸苯乙雙胍
  • 全球雙胍類藥物市場：按類型、實際和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 丁福明
  • 同時使用二甲雙胍

第7章 區域和國家分析

  • 全球雙胍類市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球雙胍類市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 雙胍類市場：競爭格局
  • 雙胍類市場：公司簡介
    • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceuticals Company Limited
  • Novo Nordisk A/S
  • Viatris Inc.
  • Daiichi Sankyo Company Limited
  • Wanbury Ltd
  • Boehringer Ingelheim International GmbH
  • Intas Pharmaceuticals Ltd.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd
  • Shionogi & Co. Ltd.
  • Dr. Reddy's Laboratories
  • Lupin Limited

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029 年雙胍類藥物市場：提供新機會的國家
  • 2029 年雙胍類藥物市場：細分領域帶來新機會
  • 雙胍類藥物市場 2029：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r29585u

Biguanides comprise a class of medications primarily employed in the treatment of type 2 diabetes. They aid in lowering blood sugar levels by reducing the liver's production of sugar and enhancing the body's responsiveness to insulin. Additionally, these medications find utility in treating polycystic ovary syndrome (PCOS) and other metabolic disorders.

The primary types of biguanides include metformin, phenformin, and others. Metformin stands out as a widely utilized biguanide medication for type 2 diabetes management, effectively lowering blood sugar levels. Available in various dosage forms such as tablets and oral solutions, metformin is offered in different formulations including immediate-release and extended-release variants. These medications are distributed through a variety of channels including hospital pharmacies, retail pharmacies, and online platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market size has grown steadily in recent years. It will grow from $4.96 billion in 2024 to $5.11 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to a rise in demand for oral hypoglycemic drugs, growth in the geriatric population, rise in obesity rates, and increased awareness about diabetes management.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.81 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to the growing adoption of combination therapies, advancements in drug delivery technologies, increasing investment in research and development, rising healthcare expenditure, and expanding applications in the treatment of polycystic ovary syndrome. Major trends in the forecast period include increasing focus on developing extended-release formulations, growing preference for fixed-dose combination therapies, expanding applications in oncology, and the emergence of novel biguanides with improved efficacy and safety profiles.

The forecast of 3.2% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. endocrinology practices by inflating prices of metformin formulations manufactured in China and Israel, resulting in delayed type 2 diabetes management and higher metabolic disorder treatment costs for 34 million American patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increase in diabetes cases is anticipated to drive the expansion of the biguanides market in the foreseeable future. Diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production, is on the rise due to various factors such as lifestyle shifts, population aging, genetic factors, improved diagnostic methods, and environmental influences. Biguanides such as metformin help manage diabetes by enhancing insulin sensitivity, reducing liver glucose production, and lowering blood sugar levels in individuals with type 2 diabetes. For example, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals receiving all eight recommended care processes for type 1 and type 2 diabetes increased significantly. Additionally, the percentage of individuals achieving target HbA1c levels reached a record high of 37.9%. Therefore, the increasing prevalence of diabetes is propelling the growth of the biguanides market.

Leading companies in the biguanides market are concentrating on developing advanced solutions such as extended-release formulations to enhance patient compliance, improve therapeutic effectiveness, and minimize side effects. Extended-release biguanides slowly release their active ingredients, ensuring consistent blood levels and better glycemic control for diabetes patients, thereby enhancing treatment adherence. For instance, in August 2023, Dr. Reddy's Laboratories, an India-based biotechnology company, introduced saxagliptin and metformin hydrochloride extended-release drugs, a generic version of KOMBIGLYZE XR approved by the US Food and Drug Administration (USFDA). This combination medication, consisting of saxagliptin, a DPP-4 inhibitor, and metformin, a biguanide, aims to improve glycemic control in adults with type 2 diabetes mellitus when used in conjunction with diet and exercise. The extended-release formulation enhances patient adherence and efficacy.

In August 2023, Lupin, an India-based biopharmaceutical company, acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This acquisition enables Lupin to expand its product portfolio and strengthen its position in the anti-diabetes segment, ensuring broader access to medication for patients. Boehringer Ingelheim, a Germany-based biopharmaceutical company, is renowned for its research, development, and production of therapies for both human and veterinary medicine.

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc, Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd, Shionogi & Co Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc, Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

Asia-Pacific was the largest region in the biguanides market in 2024. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biguanides Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biguanides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biguanides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biguanides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Metformin; Phenformin; Other Types
  • 2) By Dosage Form: Tablets; Oral Solutions
  • 3) By Formulation: Immediate Release; Extended Release
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
  • 2) By Phenformin: Phenformin Hydrochloride
  • 3) By Other Types: Buformin; Metformin Combinations
  • Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; Merck And Co Inc; Bayer AG; Sanofi-Aventis LLC; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceuticals Company Limited; Novo Nordisk A/S; Viatris Inc.; Daiichi Sankyo Company Limited; Wanbury Ltd; Boehringer Ingelheim International GmbH; Intas Pharmaceuticals Ltd.; Aurobindo Pharma Ltd.; Cipla Ltd; Shionogi & Co Ltd; Dr. Reddy's Laboratories; Lupin Limited; Zydus Lifesciences Limited; Apotex Inc; Torrent Pharmaceuticals Limited; Panacea Biotech Ltd.; Auro Laboratories Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biguanides Market Characteristics

3. Biguanides Market Trends And Strategies

4. Biguanides Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Biguanides Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Biguanides PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Biguanides Market Growth Rate Analysis
  • 5.4. Global Biguanides Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Biguanides Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Biguanides Total Addressable Market (TAM)

6. Biguanides Market Segmentation

  • 6.1. Global Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metformin
  • Phenformin
  • Other Types
  • 6.2. Global Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tablets
  • Oral Solutions
  • 6.3. Global Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immediate Release
  • Extended Release
  • 6.4. Global Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.5. Global Biguanides Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immediate-Release Metformin
  • Extended-Release Metformin
  • 6.6. Global Biguanides Market, Sub-Segmentation Of Phenformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Phenformin Hydrochloride
  • 6.7. Global Biguanides Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Buformin
  • Metformin Combinations

7. Biguanides Market Regional And Country Analysis

  • 7.1. Global Biguanides Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Biguanides Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biguanides Market

  • 8.1. Asia-Pacific Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biguanides Market

  • 9.1. China Biguanides Market Overview
  • 9.2. China Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biguanides Market

  • 10.1. India Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biguanides Market

  • 11.1. Japan Biguanides Market Overview
  • 11.2. Japan Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biguanides Market

  • 12.1. Australia Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biguanides Market

  • 13.1. Indonesia Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biguanides Market

  • 14.1. South Korea Biguanides Market Overview
  • 14.2. South Korea Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biguanides Market

  • 15.1. Western Europe Biguanides Market Overview
  • 15.2. Western Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biguanides Market

  • 16.1. UK Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biguanides Market

  • 17.1. Germany Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biguanides Market

  • 18.1. France Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biguanides Market

  • 19.1. Italy Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biguanides Market

  • 20.1. Spain Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biguanides Market

  • 21.1. Eastern Europe Biguanides Market Overview
  • 21.2. Eastern Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biguanides Market

  • 22.1. Russia Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biguanides Market

  • 23.1. North America Biguanides Market Overview
  • 23.2. North America Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biguanides Market

  • 24.1. USA Biguanides Market Overview
  • 24.2. USA Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biguanides Market

  • 25.1. Canada Biguanides Market Overview
  • 25.2. Canada Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biguanides Market

  • 26.1. South America Biguanides Market Overview
  • 26.2. South America Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biguanides Market

  • 27.1. Brazil Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biguanides Market

  • 28.1. Middle East Biguanides Market Overview
  • 28.2. Middle East Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biguanides Market

  • 29.1. Africa Biguanides Market Overview
  • 29.2. Africa Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biguanides Market Competitive Landscape And Company Profiles

  • 30.1. Biguanides Market Competitive Landscape
  • 30.2. Biguanides Market Company Profiles
    • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis

31. Biguanides Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Novartis AG
  • 31.3. GlaxoSmithKline plc
  • 31.4. Takeda Pharmaceuticals Company Limited
  • 31.5. Novo Nordisk A/S
  • 31.6. Viatris Inc.
  • 31.7. Daiichi Sankyo Company Limited
  • 31.8. Wanbury Ltd
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Intas Pharmaceuticals Ltd.
  • 31.11. Aurobindo Pharma Ltd.
  • 31.12. Cipla Ltd
  • 31.13. Shionogi & Co. Ltd.
  • 31.14. Dr. Reddy's Laboratories
  • 31.15. Lupin Limited

32. Global Biguanides Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biguanides Market

34. Recent Developments In The Biguanides Market

35. Biguanides Market High Potential Countries, Segments and Strategies

  • 35.1 Biguanides Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Biguanides Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Biguanides Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer